前蛋白转化酶枯草溶菌素9抑制剂的临床研究及应用进展

Progress in research and clinical application of proprotein convertase subtilisin kexin type 9 inhibitors in the treatment of dyslipidemia

前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂可通过抑制肝细胞表面低密度脂蛋白受体的降解对脂质代谢起到调节作用。目前已有多项临床研究证明,PCSK9抑制剂单一药物或与他汀类药物联合使用可显著降低低密度脂蛋白胆固醇水平。本文综述了当前PCSK9抑制剂的重要临床研究及应用进展,并简要总结了常见PCSK9抑制剂的安全性、有效性及临床应用现状。

Proprotein convertase subtilisin kexin type 9(PCSK9)inhibitors regulate lipid metabolism by inhibiting the degradation of low-density lipoprotein receptors on the surface of hepatocytes.Multiple clinical studies have demonstrated that the use of PCSK9 inhibitors as monotherapy or in combination with statins can significantly reduce levels of low-density lipoprotein cholesterol.This article reviews the significant clinical research and progress in the application of PCSK9 inhibitors and briefly summarizes their safety,efficacy and clinical applications.